|
KMID : 0370220200640010028
|
|
Yakhak Hoeji
2020 Volume.64 No. 1 p.28 ~ p.38
|
|
|
Clinical Responses and Follow-up Evaluation after Anti-TNF Treatment in Patients with Rheumatoid Arthritis at a Tertiary-care Hospital
|
|
Park Sun-Hee
Choe In
Choi Eun-Joo
|
|
|
Abstract
|
|
|
|
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint damage and bone erosion. Antitumornecrosis factor (anti-TNF) agents are first-line biological Disease-Modifying Anti-rheumatic Drugs (DMARDs),which can reduce the disease activity of RA. The objective of this study is to evaluate and observe the clinical responsesand parameters following anti-TNF administration. We analysed the medical records of patients who were administeredanti-TNF agent for RA, from September 2012 to August 2015, retrospectively. The clinical responses (ESR, CRP, swollenjoint count, tender joint count) and adverse effect monitoring factors (AST, ALT, white blood cell count, hemoglobin,neutrophils count, platelet count, serum creatinine) were observed before the drug administration, and follow-up observationwere also made at 3, 9, and 15-month post-administration. 104 patients of 306 patients were selected based on inclusionand exclusion criteria, and were administered etanercept (n=38), adalimumab (n=46), and infliximab (n=20). After 3months, the clinical response significantly decreased, regardless of the type of anti-TNF agents used, and the levels weremaintained up to 15 months (p<0.05). Platelet, WBC and neutrophils count decreased after 3 months of anti-TNF agentadministration, regardless of the type of anti-TNF agents used, and the levels were maintained up to 15 months (p<0.05).
|
|
|
KEYWORD
|
|
|
Anti-TNF agents, adalimumab, clinical responses, etanercept, follow-up evaluation, infliximab, Rheumatoid Arthritis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|